Skip to main content

letter

. 1994 Feb 19;308(6927):533–534. doi: 10.1136/bmj.308.6927.533b

Mesalazine toxicity.

PMCID: PMC2542804 PMID: 8166873

533

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Cambridge G., Rampton D. S., Stevens T. R., McCarthy D. A., Kamm M., Leaker B. Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1992 May;33(5):668–674. doi: 10.1136/gut.33.5.668. [DOI] [PMC free article] [PubMed] [Google Scholar]
Lim A. G., Hine K. R. Fever, vasculitic rash, arthritis, pericarditis, and pericardial effusion after mesalazine. BMJ. 1994 Jan 8;308(6921):113–113. doi: 10.1136/bmj.308.6921.113. [DOI] [PMC free article] [PubMed] [Google Scholar]
Reinoso M. A., Schroeder K. W., Pisani R. J. Lung disease associated with orally administered mesalamine for ulcerative colitis. Chest. 1992 May;101(5):1469–1471. doi: 10.1378/chest.101.5.1469. [DOI] [PubMed] [Google Scholar]
Welte T., Hamm H., Fabel H. Mesalazine alveolitis. Lancet. 1991 Nov 16;338(8777):1273–1273. doi: 10.1016/0140-6736(91)92140-w. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES